UBS Group
SEEL

UBS Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

UBS Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Hold
0
– -$2K – 9495
2014
Q4 		– Hold
0
– – – 9436

Other funds holding SEEL

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VWWMG
Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $174M AUM 15.31% 1-Year Est. Return

UBS Group's SEEL Position: Q4 2024 in Review

UBS Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 8,477 shares — an estimated $31.8K sold.

UBS Group first reported a position in SEEL in Q1 2020 and held it in 16 quarters. The position peaked at $70K in Q4 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.

  • UBS Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 8,477 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $31.8K.
  • UBS Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
  • UBS Group's Seelos Therapeutics, Inc. Common Stock position peaked at $70K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.